

April 1, 2026

To,  
**Dy. General Manager**  
Department of Corporate Services,  
BSE Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort, Mumbai – 400 001

To,  
**The Manager – Listing,**  
The National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Ref: Scrip Code: 532296**

**Ref: Scrip Name: GLENMARK**

Dear Sir,

**Sub: Glenmark Pharmaceuticals Announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS® in the U.S., Significantly Expanding its Innovative Portfolio. RYALTRIS® is Glenmark's first innovative product introduced into the U.S. market**

Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced that it will manage end-to-end commercialization and distribution for RYALTRIS® (Olopatadine Hydrochloride and Mometasone Furoate) Nasal Spray, 665 mcg/25 mcg\* per spray in the United States, effective April 1, 2026.

This marks a meaningful step in Glenmark's continued expansion in the region with a sustainable approach to building a strong, direct commercial U.S. based presence.

Kindly find attached media release which is self- explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
**For Glenmark Pharmaceuticals Limited**

**Harish Kuber**  
**Company Secretary & Compliance Officer**

*Encl: As above*

**Glenmark Pharmaceuticals Limited**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)

**Glenmark Pharmaceuticals Announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS® in the U.S., Significantly Expanding Its Innovative Portfolio**

**RYALTRIS® is Glenmark's first innovative product introduced into the U.S. market**

**Elmwood Park, New Jersey, April 01, 2026** - Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced that it will manage end-to-end commercialization and distribution for RYALTRIS® (Olopatadine Hydrochloride and Mometasone Furoate) Nasal Spray, 665 mcg/25 mcg\* per spray in the United States, effective April 1, 2026.

This marks a meaningful step in Glenmark's continued expansion in the region with a sustainable approach to building a strong, direct commercial U.S. based presence.

RYALTRIS® was launched in the United States in 2022 and is approved by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of symptoms associated with Seasonal Allergic Rhinitis (SAR) in adults and paediatric patients 12 years of age and older<sup>1</sup>. It is a fixed-dose combination nasal spray that brings together olopatadine hydrochloride (an antihistamine) and mometasone furoate (a corticosteroid) in a single formulation. The product is supplied as a 240-metered spray nasal suspension.

Seasonal Allergic Rhinitis affects millions of patients across the United States and remains an area where symptom control and treatment adherence continue to be important considerations. By combining two established therapies in one formulation, RYALTRIS® offers a convenient treatment option<sup>1</sup> aligned with evolving patient and physician preferences.

Glenmark will directly lead brand strategy, market access, and customer engagement for RYALTRIS® in the U.S. This allows for more focused execution, closer alignment with healthcare providers and greater responsiveness to market needs.

**Commenting on the development, Marc Kikuchi, President & Business Head, North America** said, "The commercialization by Glenmark for RYALTRIS® in the United States is an important step forward for the growth of our company. It allows us greater operational direction in how we engage the market and support healthcare providers and patients across the nation. Today's announcement also marks a significant moment in our broader effort to strengthen our innovative businesses in the U.S. and build a more direct, sustainable commercial presence over time."

RYALTRIS® is already approved in key markets including the United States, European Union, United Kingdom, Australia, South Korea, Russia and China. In FY26, RYALTRIS® was launched in 11 additional markets, expanding its presence to 55 countries worldwide.

\*Calculated on the anhydrous basis

<sup>1</sup>RYALTRIS® Nasal Spray approved prescribing information, Glenmark Specialty SA, Switzerland.

Please click [here](#) to view full prescribing information, including Important Safety Information.

For additional information about RYALTRIS® and how to access, please visit [us.ryaltris.com](https://us.ryaltris.com).

RYALTRIS is a registered trademark of Glenmark Specialty SA.

**About Glenmark Pharmaceuticals Limited**

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research-led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit [www.glenmarkpharma.com](https://www.glenmarkpharma.com).

**For more information, please contact**

India	United States
Akhila Natarajan   <a href="mailto:mediarelations@glenmarkpharma.com">mediarelations@glenmarkpharma.com</a> +91 98216 89525  Adfactors PR   <a href="mailto:glenmark@adfactorspr.com">glenmark@adfactorspr.com</a>   +91 88502 91322	Akhila Natarajan   <a href="mailto:mediarelations@glenmarkpharma.com">mediarelations@glenmarkpharma.com</a> +91 98216 89525  Danielle Hagen   <a href="mailto:danielle@nahigianstrategies.com">danielle@nahigianstrategies.com</a> 202-365-6112